Piper Sandler Reaffirms Neutral Rating for Envista (NYSE:NVST)

Posted by Brenda Bartman on Aug 6th, 2026

Envista (NYSE:NVST – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at Piper Sandler in a note issued to investors on Thursday,Benzinga reports. They currently have a $28.00 target price on the stock, up from their previous target price of $26.00. Piper Sandler’s price objective points to a potential upside of 0.26% from the stock’s current price.

Several other brokerages have also recently commented on NVST. Mizuho set a $29.00 price target on Envista in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Envista from $26.00 to $29.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Morgan Stanley increased their price target on shares of Envista from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Friday, April 24th. Barclays reduced their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, June 11th. Finally, Evercore reissued an “outperform” rating and set a $33.00 target price on shares of Envista in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $29.15.

Read Our Latest Stock Analysis on NVST

Envista Stock Performance

Shares of NYSE NVST traded down $0.70 during midday trading on Thursday, hitting $27.93. The company’s stock had a trading volume of 3,108,584 shares, compared to its average volume of 2,953,366. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. Envista has a 1-year low of $18.77 and a 1-year high of $30.42. The firm’s fifty day moving average price is $25.87 and its 200-day moving average price is $25.99. The firm has a market cap of $4.54 billion, a P/E ratio of 68.04, a P/E/G ratio of 1.58 and a beta of 0.86.

Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07. The business had revenue of $730.50 million during the quarter, compared to the consensus estimate of $716.11 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, sell-side analysts forecast that Envista will post 1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several large investors have recently bought and sold shares of NVST. Caitong International Asset Management Co. Ltd grew its stake in shares of Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP increased its stake in Envista by 75.4% in the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares in the last quarter. UMB Bank n.a. increased its position in shares of Envista by 46.1% in the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after buying an additional 636 shares in the last quarter. IFP Advisors Inc lifted its holdings in Envista by 102.9% during the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after acquiring an additional 1,071 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares in the last quarter.

More Envista News

Here are the key news stories impacting Envista this week:

Positive Sentiment: Quarterly earnings exceeded expectations. Envista reported adjusted EPS of $0.41, up from $0.26 a year earlier and above the $0.33–$0.34 analyst consensus. Envista Q2 Earnings and Revenues Surpass Estimates
Positive Sentiment: Revenue also beat estimates and grew year over year. Sales reached $730.5 million versus expectations of $716.1 million, representing 7.1% growth from the comparable period. Envista Q2 Earnings Snapshot
Positive Sentiment: Full-year guidance was raised or reaffirmed above consensus. Envista forecast fiscal 2026 EPS of $1.50–$1.55, compared with the current analyst consensus of approximately $1.43, signaling management confidence in future earnings. Envista 2026 Q2 Results Earnings Call Presentation
Neutral Sentiment: Management discussed the quarter and outlook on its earnings call. Investors are likely evaluating the call’s details on operating performance, demand trends and execution against the updated guidance. Envista Q2 2026 Earnings Call Transcript
Negative Sentiment: Profitability remains relatively thin. Envista’s reported net margin was 2.41%, while its price-to-earnings ratio was approximately 69. Investors may be taking profits or demanding stronger improvement before assigning additional value despite the earnings beat.

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.